Recent Postings to

Worst Pills, Best Pills Newsletter Articles

  View the entire December 2016 issue in PDF format

  • The Rising Cost of Generic Drugs
    (December 2016)
    The ever-increasing prices for prescription medications are often in the news these days, with some products carrying eye-popping price tags of more than $100,000 per year. Typically the highest prices are for newer, brand-name products. Yet a more surprising pricing story has begun to emerge over the past few years: the rising cost of generic medications.
  • FDA Leadership Ignores Science, Approves Ineffective Drug
    (December 2016)
    Learn why the decision by FDA’s leaders to approve a new medication for a rare muscle disorder, over the strenuous objections of the agency’s scientific experts, threatens to undermine public health.
  • Endocrine Society Recommends Against Routine Use of Compounded Hormones
    (December 2016)
    In this article, we explain why FDA-approved bioidentical hormone medications are preferred over custom-mixed (compounded) products for treating hormone-related disorders.
  • Ropinirole: A Second-Choice Drug for Parkinson’s Disease
    (December 2016)
    In this article, we explore recent research showing that the older drug levodopa-carbidopa has a more favorable benefit-risk balance than ropinirole and other newer dopamine agonists for initial treatment of early Parkinson’s disease.
  • Dangers of Sleep Drug Suvorexant Still Outweigh Minimal Benefits
    (December 2016)
    Find out why Public Citizen’s Health Research Group has designated suvorexant as Do Not Use and what steps you can take to improve your sleep without relying on medications.

  View the entire November 2016 issue in PDF format

  • EpiPen Maker Mylan Becomes Lead Pharma Villain
    (November 2016)
    Worst Pills, Best Pills News editor Dr. Michael Carome discusses how drug manufacturer Mylan assumed the banner of most infamous price gouger among pharmaceutical corporations in the U.S.
  • Adding Aliskiren to an ACE Inhibitor in Heart Failure Harmful, Without Benefit
    (November 2016)
    For many years we have recommended never combining the high blood pressure medications aliskiren and ACE inhibitors. In this article, we review new research showing that this combination of drugs poses unacceptable risks in heart failure patients and provides no additional benefit over an ACE inhibitor alone.
  • Oral Treatments for Hypothyroidism
    (November 2016)
    Not all thyroid hormone replacement medications are the same, and some are not even approved for use in the U.S. Learn which of these medications you should take — and which ones you should not take — to treat hypothyroidism (underactive thyroid).
  • Insulin Glargine (TOUJEO): Do Not Use for Seven Years
    (November 2016)
    TOUJEO is a newer, long-acting, once-daily insulin approved by the Food and Drug Administration for the treatment of Type 1 and Type 2 diabetes in adults. Learn why you should avoid using this drug until at least 2022.
  • News Brief for November 2016
    (November 2016)
    In this month's News Brief section, we report on action taken by the Food and Drug Administration to add important new warnings to the labeling of all opioid and benzodiazepines drugs.
  • Commonly Used Antibiotic Can Cause Serious Psychiatric Side Effects
    (November 2016)
    Find out which commonly used antibiotic can cause psychosis, hallucinations, delirium, mood disorders, sleep disturbances and cognitive impairment.

  View the entire October 2016 issue in PDF format

  • A Guide to Treatment for ADHD
    (October 2016)
    The number of children diagnosed with attention deficit hyperactivity disorder (ADHD) and treated with drugs has increased dramatically over the past decade. Learn the steps needed for an accurate ADHD diagnosis and understand the variety of treatments available before working with your child's doctor on a plan for treatment.
  • Most Patients’ Groups Opposing Medicare Drug Pricing Reforms Have Ties to Big Pharma
    (October 2016)
    Worst Pills, Best Pills News editor Dr. Michael Carome discusses the implications of a recent Public Citizen report showing that the overwhelming majority of patient groups that opposed a recent Medicare Part B plan to rein in drug costs have financial ties to pharmaceutical corporations.
  • Treatment of Bacterial Skin Infections
    (October 2016)
    Bacterial skin infections are very common, resulting in several million visits to health care professionals annually. In this article, we explain the best treatment options for different types of bacterial skin infections.
  • FDA Issues Multiple Warnings For Newest Class of Diabetes Drugs
    (October 2016)
    Over the past year, the Food and Drug Administration has issued a series of new warnings about serious and, in some cases, potentially fatal events linked to the newest class of diabetes drugs. These drugs, known as "flozins," are being heavily promoted in TV ads. Learn more about these newly identified dangers and why you should avoid all flozins.
  • First-Choice Treatment for Young Children With ADHD Largely Underused
    (October 2016)
    For children younger than 6 with ADHD, drug treatment is not the first choice. Find out the non-drug approach recommended by the American Academy of Pediatrics that parents and teachers can use to manage these very young ADHD patients.
  • Questions & Answers
    (October 2016)
    n this month Questions & Answers section, we respond to a reader's question asking for advice on how patients can find out if their doctors have taken money from the pharmaceutical industry.

Additional Information from Public Citizen

Copyright © 2016 Public Citizen's Health Research Group. All rights reserved.